Pharma Absent From 2013 M&A, But Expect Tides To Turn, Says EY
This article was originally published in The Pink Sheet Daily
Executive Summary
Big pharma was conspicuously absent from the M&A playing field in 2013, Ernst & Young points out in a report, but big biotech and specialty pharmas are making the deal landscape more competitive.
You may also be interested in...
Valeant Has Big Plans To Become A Big Pharma In Coming Year
The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.